Human Oncology & Pathogenesis Program
The Christine Iacobuzio-Donahue Lab
Our lab investigates the fundamental evolutionary mechanisms underlying metastasis using pancreatic cancer as our model tumor type. Metastasis is the result of a series of biological hurdles subject to Darwinian selection including the birth of metastasis-enabled cells within a heterogeneous primary tumor microenvironment, intravasation of these cells into a functional vascular bed, survival in the circulation, extravasation from the vasculature, and establishment of an autonomous cell population within the newly encountered foreign microenvironment.
Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. Kim MS, Zhong Y, Yachida S, Rajeshkumar NV, Abel ML, Marimuthu A, Mudgal K, Hruban RH, Poling JS, Tyner JW, Maitra A, Iacobuzio-Donahue CA*, Pandey A. Mol Cell Proteomics. 2014 Jun 3. pii: mcp.M114.038547. *co-senior author
Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Yachida S, White CM, Naito Y, Zhong Y, Brosnan JA, Macgregor-Das AM, Morgan RA, Saunders T, Laheru DA, Herman JM, Hruban RH, Klein AP, Jones S, Velculescu V, Wolfgang CL, Iacobuzio-Donahue CA. Clin Cancer Res. 2012 Nov 15;18(22):6339-47.
Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA*, Michor F. Cell. 2012 Jan 20;148(1-2):362-75. *co-senior author
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Nature. 2010 Oct 28;467(7319):1114-7.
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, Herman JM, Cameron JL, Yeo CJ, Halushka MK, Eshleman JR, Raben M, Klein AP, Hruban RH, Hidalgo M, Laheru D. J Clin Oncol. 2009 Apr 10;27(11):1806-13.
Christine A. Iacobuzio-Donahue, MD, PhD
David M. Rubenstein Center Chair for Pancreatic Cancer Research; Director, Center for Pancreatic Cancer Research
- Physician-scientist Christine Iacobuzio-Donahue studies the genomics and cell biology of pancreatic and other solid tumors as it relates to subclonal evolution, tumor progression, and metastasis.
- MD, PhD, Boston University
- View physician profile
- Physician profile
- Team Science Award, American Association for Cancer Research (2012)
- Ramzi Cotran Young Investigator Award, United States and Canadian Academy of Pathology (2009)
- AACR-Barletta Foundation Career Development Award in Translational Pancreatic Cancer Research (2005)
- Member, Alpha Omega Alpha (2002)
- American Society of Clinical Investigators (2015)
- Elected to American Association of University Pathologists (Pluto Society)
To learn more about available postdoctoral opportunities, please visit our Career Center
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Christine A. Iacobuzio-Donahue discloses the following relationships and financial interests:
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.